What is the significance of finding modulating anti-acetylcholine receptor (AChR) ab in the evaluation of myasthenia gravis (MG)?

Updated: Aug 27, 2018
  • Author: Abbas Jowkar, MD; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
  • Print
Answer

2%–4% of MG cases with negative AChR-ab (binding) will have the modulating antibody. It is implicated with an increased risk of thymoma. 73% of patients with thymoma and MG will have modulating antibodies. [43]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!